atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
ChatEHR, artificial intelligence software developed at Stanford Medicine, is expediting chart reviews and other tasks by allowing clinicians to ask questions of medical records.
Read more here.
As meaning-makers, we use spoken or signed language to understand our experiences in the world around us. The emergence of generative artificial intelligence such as ChatGPT (using large language models) call into question the very notion of how to define “meaning.”
Read more here.
Attendees
Sponsors and Exhibitors
Contact us